European regulators are recommending approval for two rare disease treatments from Alexion, a victory for the biotech as it works to expand its stable of commercialized drugs. …read more Source: Alexion gets EU green light for a pair of rare disease drugs
Bristol-Myers Squibb’s latest R&D reshuffle calls for a consolidated presence in Cambridge, MA’s booming Kendall Square, and the drugmaker has signed on to serve as anchor tenant in the area’s next big research facility, joining Big Pharma’s ongoing colonization of a biotech hotbed. …read more Source: Bristol-Myers is the next big tenant in biotech’s hottest […]
Biotech billionaire Patrick Soon-Shiong is pumping $71 million into Conkwest as it preps a move to go public in a $172.5 million IPO. …read more Source: Billionaire Soon-Shiong arranges a $71M crossover round for Conkwest
…read more Source: Viehbacher returns to lead Swiss billionaire’s $2B biotech fund
Cambridge, MA’s Seres Therapeutics pulled off an above-its-range IPO, grossing about $134 million to bankroll its work on drugs that change the weather in the gut to treat disease. …read more Source: Seres guts out a $134M IPO to fuel microbiome R&D
In this week’s EuroBiotech Report, two corners of Britain’s great hope for competing with the likes of Boston and San Francisco, the area dubbed the “golden triangle,” spent the week talking about the one area in which they indisputably fall short of their rivals: Cash. And more. …read more Source: Google backs £320M Oxford fund, […]
Allergan, still working through its $66 billion merger with Actavis, is through shedding jobs at its California headquarters, CEO Brent Saunders said, moving on from laying off more than 1,000 workers over the past year. …read more Source: Allergan calls a cease-fire after thousands of job cuts at its HQ
The gene-sequencing pioneers at Illumina are planning to build a major new science center and European headquarters in the U.K.’s growing biotech hub in Cambridge. Illumina signed a lease on a 155,000-square-foot facility, designed to grow another 70,000 square feet as needed for future expansion. …read more Source: Genomics giant Illumina blueprints new Euro HQ/science […]
Catabasis, at work on treatments for muscular dystrophy and high cholesterol, raised $60 million in an IPO, cashing in on investors’ continued enthusiasm for bets on biotech companies. …read more Source: Catabasis pulls off a $60M IPO as biotech’s Wall Street window stays open
AbbVie has walked away from its claim to Biotest’s anti-CD4 monoclonal antibody, tregalizumab. The decision comes two months after Biotest posted Phase IIb data showing tregalizumab failed to outperform the placebo in terms of improvements to ACR20 scores. …read more Source: AbbVie hands back rights to Biotest’s RA drug after trial flop
